Medicare will cover expensive new leukemia medication

Medicare will cover expensive new leukemia medication

(HealthDay)—Medicare will pay for a new, expensive cancer medication that costs about $178,000 for a standard course of treatment, the Obama administration says.

Beginning Oct. 1, Medicare will make additional payments for patients with a particularly aggressive type of leukemia to receive Amgen's Blincyto (blinatumomab), The New York Times reported.

The announcement reverses a preliminary decision in April, when the government said Medicare would not pay extra for Blincyto because were "not sufficient to demonstrate" that it offered substantial benefits to patients with . However, the final rule to be published in the Federal Register on Aug. 17 says the administration received "additional information and input" from Amgen and other experts and now agrees with their opinion, The Times reported.

That means that Blincyto qualifies for special "add-on payments" that Medicare makes to hospitals for new treatments whose costs are not yet included in standard lump-sum payments for treating patients with a particular health problem.

More information: Health Highlights: Aug 10, 2015

Copyright © 2015 HealthDay. All rights reserved.

Citation: Medicare will cover expensive new leukemia medication (2015, August 11) retrieved 28 March 2024 from https://medicalxpress.com/news/2015-08-medicare-expensive-leukemia-medication.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Blincyto approved for rare leukemia

10 shares

Feedback to editors